Skip to main content
Go to homepage

Omaveloxolone for patients with mitochondrial myopathy

Omaveloxolone (RTA 408) for patients with mitochondrial myopathy


We want to learn if a new medicine can help patients with mitochondrial myopathy—a condition causing muscle loss.  Mitochondria are the body’s “power plants.” They convert food into energy the body needs to function. If these “power plants” don’t produce enough energy, muscle weakness and fatigue can result.

In this study, patients diagnosed with mitochondrial myopathy will receive the study drug Omaveloxolone (RTA 408) or a pill without this medicine (a placebo). We will follow patients to see if the drug is safe and might improve their symptoms.

RTA 408 is an experimental drug being tested by the FDA (Food and Drug Administration).

For more information on this study, visit:

Who May Qualify?:

Male or female mitochondrial myopathy patients 18 through 75 years of age.

We will screen potential study participants for additional criteria.

Who Does Not Qualify:

For detailed information on qualifying for enrollment visit:

Interested in participating?
We are currently recruiting
Study Sponsor:

Reata Pharmaceuticals, Inc.

Full IRB Study Title:
A Phase 2 Study of the Safety, Efficacy and Pharmacodynamics of RTA 408 in the Treatment of Mitochondrial Myopathy
IRB Study ID:
If you are interested in this study or have questions about your child's eligibility, please contact:

Rebecca D. Considine Research Institute, 330-543-5012

Lead Investigator
Bruce H. Cohen, MD, FAAN

Director, NeuroDevelopmental Science Center; Pediatric Neurologist
Pediatric Brain Tumor ProgramPediatric Neurology